Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

963 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO 3rd, Duncan B, Goel N, Davies OR, Dougados M. Weinblatt ME, et al. Among authors: duncan b. Rheumatology (Oxford). 2012 Dec;51(12):2204-14. doi: 10.1093/rheumatology/kes150. Epub 2012 Aug 25. Rheumatology (Oxford). 2012. PMID: 22923753 Clinical Trial.
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M. Weinblatt ME, et al. Among authors: duncan b. Arthritis Res Ther. 2015 Nov 15;17:325. doi: 10.1186/s13075-015-0841-9. Arthritis Res Ther. 2015. PMID: 26568428 Free PMC article. Clinical Trial.
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.
Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K. Genovese MC, et al. Among authors: duncan b. Ann Rheum Dis. 2014 Sep;73(9):1607-15. doi: 10.1136/annrheumdis-2013-204760. Epub 2014 Mar 18. Ann Rheum Dis. 2014. PMID: 24641941 Free PMC article. Clinical Trial.
KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, Buyle S, Hallström Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B; KOMET Study Group. Trinka E, et al. Among authors: duncan b. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1138-47. doi: 10.1136/jnnp-2011-300376. Epub 2012 Aug 29. J Neurol Neurosurg Psychiatry. 2013. PMID: 22933814 Clinical Trial.
Call to action for Clinicians in the South-East Asian Regions on Primary Prevention of Diabetes in people with Prediabetes- A Consensus statement.
Ramachandran A, Nanditha A, Tuomilehto J, Gabriel R, Sahoo B, Mohan V, Chawla M, Chawla P, Raghavan A, Gupta A, Joshi S, Agarwal S, Misra A, Sahay R, Tiwaskar MH, Azad Khan AK, Arvind SR, Viswanathan V, Das AK, Makkar BM, Kowlessur S, Yajnik CS, Sriram U, Seshadri KG, Susairaj P, Krishnamoorthy S, Duncan BB, Aschner P, Barengo NC, Schwarz PE, Ceriello A. Ramachandran A, et al. Among authors: duncan bb. Diabetes Res Clin Pract. 2025 Jan 13:111997. doi: 10.1016/j.diabres.2025.111997. Online ahead of print. Diabetes Res Clin Pract. 2025. PMID: 39814235 Review.
963 results